The Patent Finder

Kyntra Bio, Inc.

Also on record
Records under this name other than the patents Kyntra Bio, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 19 patents it holds.

Showing 1 to 6 of 6 · Back to Kyntra Bio, Inc.

PatentTitleStatus Expires Confidence
US 7,713,986Compounds and Methods for Treatment of Chemotherapy-Induced Anemia
Term ended
Term ended Jun 15, 2026 · High confidence
Term endedTerm ended Jun 15, 2026High confidence
US 7,629,357Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof
Term ended
Term ended Jun 8, 2026 · Medium confidence
Term endedTerm ended Jun 8, 2026Medium confidence
US 7,618,940Fat Regulation
Term ended
Term ended Apr 3, 2026 · High confidence
Term endedTerm ended Apr 3, 2026High confidence
US 9,000,006Novel Thienopyridine Compounds, and Methods of Use Thereof
Term ended
Term ended Mar 2, 2026 · Medium confidence
Term endedTerm ended Mar 2, 2026Medium confidence
US 8,017,625Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof
Term ended
Term ended Mar 1, 2026 · High confidence
Term endedTerm ended Mar 1, 2026High confidence
19/589,689[(4-Hydroxy-1-Methyl-7-Phenoxyisoquinoline-3-Carbonyl)AMINO]ACETIC Acid (ROXADUSTAT) for the Treatment of Anemia in Subjects with Myelodysplastic Syndrome (MDS)
held by Fibrogen International (Hong Kong) Limited
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited